TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38705167

Group type: EXPERIMENTAL
Intervention: Seralutinib (60 mg twice daily for 2 weeks, then increased to 90 mg twice daily as tolerated)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (dry powder inhaler, twice daily for 24 weeks)
Number of subjects: 86
Study: 38705225

Group type: EXPERIMENTAL
Intervention: Single-incision sling (Altis sling, Coloplast)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Retropubic sling
Number of subjects: 280
Study: 38705341

Group type: EXPERIMENTAL
Intervention: Obicetrapib 10 mg
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2886
Study: 38705463

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 65
Study: 38705488

Group type: EXPERIMENTAL
Intervention: Stereotactic body RT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conventional fractionated intensity-modulated RT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 48
Study: 38705489

Group type: EXPERIMENTAL
Intervention: rhSOD enema during CCRT
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (no enema)
Number of subjects: 283
Study: 38705804

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (5 × 10^10 viral particles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (various dose levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (single dose schedule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38705820

Group type: EXPERIMENTAL
Intervention: 10-week lifestyle camp
Number of subjects: 185
Study: 38705885

Group type: EXPERIMENTAL
Intervention: Haplo-cord HCT
Number of subjects: 268

Group type: COMPARATOR
Intervention: Haplo-HCT
Number of subjects: 268
Study: 38705907

Group type: EXPERIMENTAL
Intervention: Retroseptal transconjunctival lower blepharoplasty with TTL and ORL release and resected orbital fat grafting
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Global aesthetic improvement scale (GAIS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blepharoplasty outcomes evaluation (BOE)
Number of subjects: 40
Study: 38705943

Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 139
Study: 38706247

Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every three weeks (Q3 W) for up to 24 months until progressive disease (PD) or adverse events (AE) discovery.
Number of subjects: 0
Study: 38706271

Group type: EXPERIMENTAL
Intervention: Neflamapimod 40mg capsules, twice-a-day (BID) or three-times-a-day (TID), for 16 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Neflamapimod 40mg TID
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Neflamapimod
Number of subjects: 91
Study: 38706390

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (one intravenous injection)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (one injection of saline solution)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 38706592

Group type: EXPERIMENTAL
Intervention: vebreltinib
Number of subjects: 1

Group type: COMPARATOR
Intervention: tepotinib
Number of subjects: 1
Study: 38706610

Group type: EXPERIMENTAL
Intervention: LMB-100 (30-minute infusion on days 4, 6, and 8 at doses of 100 and 140 µg/kg) + tofacitinib (10 mg BID for the first 10 days of the cycle)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LMB-100 + tofacitinib
Number of subjects: 16
Study: 38706611

Group type: EXPERIMENTAL
Intervention: QUS-radiomics model-guided adaptive chemotherapy (experimental arm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard anthracycline and taxane-based NAC (standard arm)
Number of subjects: 60
Study: 38706726

Group type: EXPERIMENTAL
Intervention: 64 Gy salvage radiotherapy (sRT)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: 70 Gy salvage radiotherapy (sRT)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Baseline G3 ED
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Baseline G0-2 ED
Number of subjects: 344

Group type: COMPARATOR
Intervention: Dose intensified sRT (64 Gy vs 70 Gy)
Number of subjects: 344
Study: 38707635

Group type: EXPERIMENTAL
Intervention: Modified breast pump suction pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard breast pump suction pattern
Number of subjects: 0
Study: 38707876

Group type: EXPERIMENTAL
Intervention: Lateral Suspension (LS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sacropexy
Number of subjects: 73
Study: 38708017

Group type: EXPERIMENTAL
Intervention: Group hypnosis program for stress reduction (5 weekly sessions) plus 5 hypnosis audio recordings and an educational booklet on coping with stress
Number of subjects: 47
Study: 38708072

Group type: EXPERIMENTAL
Intervention: PWP co-facilitated intervention delivered over six weekly sessions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no access to psychological support)
Number of subjects: 34
Study: 38708595

Group type: EXPERIMENTAL
Intervention: Cross-Seal suture-mediated vascular closure device
Number of subjects: 147
Study: 38708601

Group type: EXPERIMENTAL
Intervention: FMF preterm preeclampsia screening test (cutoff of ≥1 in 110)
Number of subjects: 7554

Group type: COMPARATOR
Intervention: American College of Obstetricians and Gynecologists criteria
Number of subjects: 7554
Study: 38708609

Group type: EXPERIMENTAL
Intervention: Impella-supported high-risk PCI
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Intra Aortic Balloon Pump (IABP)
Number of subjects: 1052
Study: 38708880

Group type: EXPERIMENTAL
Intervention: Early cold stored platelet transfusion (single apheresis cold stored platelet unit, stored for up to 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early cold stored platelet transfusion
Number of subjects: 0
Study: 38708959

Group type: EXPERIMENTAL
Intervention: Non-pooled, multidonor faecal microbiota transplantation (FMT) for 4 weeks, delivered daily by enema for 2 weeks, followed by every second day for 2 weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Non-pooled, multidonor faecal microbiota transplantation (FMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38709006

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir with oral lead-in (OLI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting cabotegravir without oral lead-in (OLI)
Number of subjects: 0
Study: 38709212

Group type: EXPERIMENTAL
Intervention: Sequential dosing of sacituzumab govitecan (SG) followed by talazoparib (TZP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Concurrent dosing of sacituzumab govitecan (SG) with talazoparib (TZP)
Number of subjects: 30
Study: 38709215

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 214
Study: 38709220

Group type: EXPERIMENTAL
Intervention: FAP-IL2v 10 mg plus atezolizumab 1,200 mg intravenously every 3 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FAP-IL2v weekly for 4 weeks and then every 2 weeks plus atezolizumab 840 mg intravenously every 2 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab
Number of subjects: 34
Study: 38709228

Group type: EXPERIMENTAL
Intervention: EDIT-101 (low dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EDIT-101 (intermediate dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EDIT-101 (high dose)
Number of subjects: 14
Study: 38709329

Group type: EXPERIMENTAL
Intervention: PostpartumCare.ca (web-enabled psychoeducational resource) for four weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 103
Study: 38709456

Group type: EXPERIMENTAL
Intervention: Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery
Number of subjects: 0
Study: 38709500

Group type: EXPERIMENTAL
Intervention: Cytisinicline, 3 mg, taken 3 times daily (n=107)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (n=53)
Number of subjects: 160
Study: 38709509

Group type: EXPERIMENTAL
Intervention: Bulk order for mammogram
Number of subjects: 24632

Group type: COMPARATOR
Intervention: No order
Number of subjects: 24632

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 24632

Group type: COMPARATOR
Intervention: No text message reminders
Number of subjects: 24632

Group type: EXPERIMENTAL
Intervention: Clinician endorsement
Number of subjects: 24632

Group type: COMPARATOR
Intervention: Standard messaging
Number of subjects: 24632
Study: 38709535

Group type: COMPARATOR
Intervention: Normothermia (n=34)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 48-hour hypothermia (33.5 °C) (n=31)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 72-hour hypothermia (33.5 °C) (n=36)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 101
Study: 38709534

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 38709550

Group type: EXPERIMENTAL
Intervention: Comunică intervention (8 live text-based counseling sessions on a mobile platform)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Content-matched education attention control (8 time-matched educational modules)
Number of subjects: 305
Study: 38709554

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) scenario
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Didactic intervention (educational video)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wearable device for continuous data collection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre-post comparison analysis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Machine learning for personal digital phenotype profile
Number of subjects: 100
Study: 38709654

Group type: EXPERIMENTAL
Intervention: Interlimb coordination
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Temporal symmetry
Number of subjects: 56
Study: 38709718

Group type: EXPERIMENTAL
Intervention: Azithromycin (AA-AA-AA-AA-A)
Number of subjects: 5340

Group type: EXPERIMENTAL
Intervention: Azithromycin (PP-PP-AA-AA-A)
Number of subjects: 5340

Group type: COMPARATOR
Intervention: Placebo (AA-AA-AA-PP-P)
Number of subjects: 5340

Group type: COMPARATOR
Intervention: Placebo (PP-PP-AA-PP-P)
Number of subjects: 5340
Study: 38709746

Group type: EXPERIMENTAL
Intervention: MARS-PD intervention alongside standard care
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study: 38709803

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cube containing vitamin A, folic acid, vitamin B12, iron, zinc, and iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bouillon cube containing iodine only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bouillon cube
Number of subjects: 0
Study: 38709986

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg once daily for 6 weeks, titrated to 10 mg once daily for 18 weeks)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 276
Study: 38709999

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) selected by noncontrast CT (NCCT)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 839
Study: 38710003

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 246

Group type: COMPARATOR
Intervention: PF
Number of subjects: 246
Study: 38710013

Group type: EXPERIMENTAL
Intervention: Liberal activity (allowed to resume activity at their discretion)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Restricted activity (avoidance of strenuous exercise and heavy lifting)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Liberal activity
Number of subjects: 158

Group type: COMPARATOR
Intervention: Restricted activity
Number of subjects: 158
Study: 38710048

Group type: EXPERIMENTAL
Intervention: Consilium Care app (ePROs)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Chemotherapy subgroup (Consilium Care app)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (matched retrospective data)
Number of subjects: 178
Study: 38710093

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound of the temporal artery as a first-line diagnostic test
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Temporal artery biopsy (TAB) as a secondary test
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clinical expertise and/or other imaging tests
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound of the temporal artery
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Alternative diagnosis
Number of subjects: 165
Study: 38710185

Group type: EXPERIMENTAL
Intervention: Garadacimab 200 mg once monthly
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Garadacimab 600 mg once monthly
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 38710187

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg every 3 weeks by intravenous infusion)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 102
Study: 38710192

Group type: EXPERIMENTAL
Intervention: Herpes zoster subunit vaccine (0.5 mL intramuscular injection) at weeks 0 and 8
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (0.5 mL intramuscular injection) at weeks 0 and 8
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Herpes zoster subunit vaccine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 38710269

Group type: EXPERIMENTAL
Intervention: 1-g conjugated estrogen cream (0.625 mg/g), inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo cream, inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 1-g conjugated estrogen cream (0.625 mg/g)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both groups (estrogen and placebo)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Estrogen group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 206
Study: 38710268

Group type: EXPERIMENTAL
Intervention: Patient grading of adverse events (mild, moderate, severe/very severe/life-threatening)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Patient grading of adverse events
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Initial patient grading of the most severe reported adverse event
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Initial grading of 'severe' adverse events
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Patient grading of adverse events over time
Number of subjects: 360
Study: 38710323

Group type: EXPERIMENTAL
Intervention: Optimization of cerebral oxygenation based on regional cerebral oxygen saturation (rSO2) monitoring
Number of subjects: 879

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 879
Study: 38710325

Group type: EXPERIMENTAL
Intervention: Preoperative ketamine 0.5 mg/kg intravenous bolus
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 38710379

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 774

Group type: COMPARATOR
Intervention: No-touch (NT) vein graft
Number of subjects: 774
Study: 38710426

Group type: EXPERIMENTAL
Intervention: Asynchronous telerehabilitation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Booklet-based rehabilitation
Number of subjects: 35
Study: 38710437

Group type: EXPERIMENTAL
Intervention: CONNACT intervention (exercise, education, psychological and nutrition)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual hospital care (control)
Number of subjects: 110
Study: 38710445

Group type: COMPARATOR
Intervention: HSP+ (45 g HSP + 5 g HSP-derived bioactive peptides/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: HSP (50 g HSP/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Casein (50 g casein/d)
Number of subjects: 35
Study: 38710463

Group type: EXPERIMENTAL
Intervention: Intrapleural tPA and deoxyribonuclease
Number of subjects: 10
Study: 38710487

Group type: EXPERIMENTAL
Intervention: 160 mg once daily (QD) 3 days on, 4 days off (160 3/4)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 120 mg QD 3 days on, 4 days off (120 3/4)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 160 mg QD 3 days on, 4 days off, 2 weeks on, 1 week off (160 3/4, 2/1w)
Number of subjects: 119
Study: 38710537

Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (137 mEq/L)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard dialysate sodium (140 mEq/L)
Number of subjects: 29
Study: 38710539

Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Traditional systemic treatment
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Nonsystemic treatment
Number of subjects: 2371

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Existing psoriatic lesions
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2371
Study: 38710583

Group type: EXPERIMENTAL
Intervention: Minimally invasive non-surgical therapy (MINST)
Number of subjects: 84
Study: 38710641

Group type: EXPERIMENTAL
Intervention: CAD/CAM custom-milled allogeneic bone blocks (CCBB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prefabricated allogeneic bone blocks (PBB)
Number of subjects: 19
Study: 38710669

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement with contemporary surgical aortic valves (10 valve models, all tissue valves; n=2938 patients)
Number of subjects: 2958
Study: 38710888

Group type: EXPERIMENTAL
Intervention: Permanent tacks
Number of subjects: 338

Group type: COMPARATOR
Intervention: Absorbable tacks
Number of subjects: 338
Study: 38710920

Group type: EXPERIMENTAL
Intervention: Nuvastatic™ 1000 mg thrice daily for 9 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 38710951

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 107
Study: 38710966

Group type: EXPERIMENTAL
Intervention: SCACOMS (Spinocerebellar Ataxia Composite Scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCACOMS-derived estimate
Number of subjects: 0
Study: 38710978

Group type: EXPERIMENTAL
Intervention: Eucaloric high-fat diet (HFD) for one month
Number of subjects: 18
Study: 38710996

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine (650 mg/m² twice daily for 1 year)
Number of subjects: 28
Study: 38711010

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard preoperative fasting
Number of subjects: 34
Study: 38711048

Group type: EXPERIMENTAL
Intervention: TIME intervention (intervention group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 150
Study: 38711112

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Point-of-care (POC) glucose testing
Number of subjects: 166
Study: 38711161

Group type: EXPERIMENTAL
Intervention: Muller maneuver
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tidal breathing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Apnea
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement
Number of subjects: 21
Study: 38711198

Group type: EXPERIMENTAL
Intervention: Radiomics combined with a conventional plaque morphological and compositional metric-based model
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Radiomic model alone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional model alone
Number of subjects: 55
Study: 38711253

Group type: EXPERIMENTAL
Intervention: Venetoclax plus azacitidine (75 mg/m²)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine
Number of subjects: 60
Study: 38711376

Group type: EXPERIMENTAL
Intervention: Neuronavigated rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both rTMS and Sham
Number of subjects: 10
Study: 38711791

Group type: EXPERIMENTAL
Intervention: PH group
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study: 38711834

Group type: EXPERIMENTAL
Intervention: Lower oxygenation target
Number of subjects: 563

Group type: COMPARATOR
Intervention: Higher oxygenation target
Number of subjects: 563
Study: 38711854

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin + pembrolizumab
Number of subjects: 0
Study: 38712133

Group type: EXPERIMENTAL
Intervention: Sorafenib tosylate, valproic acid, and sildenafil
Number of subjects: 33
Study: 38712176

Group type: COMPARATOR
Intervention: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long course chemoradiation (LCRT)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long course chemoradiation (LCRT)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Not applicable (Phase III portion)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Not applicable (Secondary objectives)
Number of subjects: 760
Study: 38712567

Group type: EXPERIMENTAL
Intervention: TXT (anti-hypotensive therapy)
Number of subjects: 66

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 66
Study: 38712616

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines
Number of subjects: 0
Study: 38712895

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0